Efficacy and genomic analysis of HER2-mutant, metastatic triple-negative breast cancer treated with neratinib alone or in combination with trastuzumab in the phase 2 SUMMIT basket trial Meeting Abstract
| Authors: | Jhaveri, K. L.; Hurvitz, S. A.; Brufsky, A.; Bose, R.; de Miguel, M. J.; Evron, E.; Unni, N.; Reid, S. A.; Quinn, D. I.; Mahalingam, D.; Saura, C.; García-Sáenz, J. A.; Martinez-Bueno, A.; Guerrero, A.; De La Fouchardiere, C.; Wildiers, H.; Bischof, G. F.; Bebchuk, J. D.; Eli, L. D.; Solit, D. B. |
| Abstract Title: | Efficacy and genomic analysis of HER2-mutant, metastatic triple-negative breast cancer treated with neratinib alone or in combination with trastuzumab in the phase 2 SUMMIT basket trial |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557400203 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.1094 |
| Notes: | Meeting Abstract: 1094 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work